NASDAQ:ZLAB Zai Lab (ZLAB) Stock Price, News & Analysis → Write this ticker symbol down… (From StocksToTrade) (Ad) Free ZLAB Stock Alerts $17.96 -0.50 (-2.71%) (As of 05/29/2024 ET) Add Compare Share Share Today's Range$17.52▼$18.0950-Day Range$13.72▼$21.5552-Week Range$13.48▼$37.92Volume356,007 shsAverage Volume758,980 shsMarket Capitalization$1.78 billionP/E RatioN/ADividend YieldN/APrice Target$64.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Zai Lab alerts: Email Address Zai Lab MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside257.6% Upside$64.22 Price TargetShort InterestHealthy3.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.83Based on 4 Articles This WeekInsider TradingSelling Shares$421,808 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.06) to ($1.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.44 out of 5 starsMedical Sector552nd out of 932 stocksPharmaceutical Preparations Industry258th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZai Lab has received no research coverage in the past 90 days.Read more about Zai Lab's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.31% of the outstanding shares of Zai Lab have been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Zai Lab has recently decreased by 24.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZLAB. Previous Next 2.1 News and Social Media Coverage News SentimentZai Lab has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Zai Lab this week, compared to 4 articles on an average week.Search Interest4 people have searched for ZLAB on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $421,808.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zai Lab's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($3.06) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zai Lab's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Zai Lab Stock (NASDAQ:ZLAB)Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.Read More ZLAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZLAB Stock News HeadlinesMay 17, 2024 | insidertrades.comZai Lab Limited (NASDAQ:ZLAB) Insider Sells $213,300.00 in StockMay 22, 2024 | businesswire.comZai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque PsoriasisMay 20, 2024 | markets.businessinsider.comZai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+May 20, 2024 | businesswire.comZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in ChinaMay 17, 2024 | finance.yahoo.comInsider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells SharesMay 16, 2024 | finance.yahoo.comZai Lab Announces Participation in May and June Investor ConferencesMay 16, 2024 | businesswire.comZai Lab Announces Participation in May and June Investor ConferencesMay 15, 2024 | markets.businessinsider.comAnalyst Upgrades Zai Lab’s Price Objective on Strong Drug Portfolio and Growth ProspectsMay 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Zai Lab (ZLAB), Alphatec Holdings (ATEC)May 14, 2024 | businesswire.comZai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in ChinaMay 13, 2024 | marketwatch.comZai Lab Shares Rise 11% After Augtyro NDA Approved in ChinaMay 13, 2024 | stockhouse.comZai Lab Announces Approval of AUGTYRO(TM) (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPAMay 13, 2024 | markets.businessinsider.comChina Approves Zai Lab's AUGTYRO For ROS1-Positive NSCLC TreatmentMay 12, 2024 | businesswire.comZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPAMay 11, 2024 | finance.yahoo.comZai Lab Limited (NASDAQ:ZLAB) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 10, 2024 | finance.yahoo.comZai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketwatch.comZai Labs Shares Rise 26% After Narrower-Than-Expected 1Q LossMay 8, 2024 | investorplace.comZLAB Stock Earnings: Zai Lab Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from Zai Lab's earnings reportMay 7, 2024 | markets.businessinsider.comHere's what Wall Street expects from Zai Lab's earningsApril 30, 2024 | finance.yahoo.comZai Lab Limited's (NASDAQ:ZLAB) Profit OutlookApril 21, 2024 | wsj.comZai Lab Ltd. ADRApril 19, 2024 | finance.yahoo.comZai Lab Limited (ZLAB)April 16, 2024 | seekingalpha.comA Risky Bet: Zai Lab's Uncertain FutureSee More Headlines Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/30/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZLAB CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees2,175Year FoundedN/APrice Target and Rating Average Stock Price Target$64.22 High Stock Price Target$73.34 Low Stock Price Target$47.50 Potential Upside/Downside+257.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-334,620,000.00 Net Margins-116.45% Pretax Margin-116.45% Return on Equity-40.21% Return on Assets-32.48% Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio4.43 Sales & Book Value Annual Sales$266.72 million Price / Sales6.68 Cash FlowN/A Price / Cash FlowN/A Book Value$7.68 per share Price / Book2.34Miscellaneous Outstanding Shares99,210,000Free Float94,020,000Market Cap$1.78 billion OptionableOptionable Beta1.11 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Ying Du Ph.D. (Age 58)Founder, Chairperson & CEO Comp: $1.67MMr. Joshua L. Smiley (Age 54)President & COO Comp: $647.11kDr. Rafael G. Amado M.D. (Age 60)President and Head of Global Oncology Research & Development Comp: $477kDr. Harald Reinhart M.D. (Age 72)President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases Comp: $923.33kDr. Yajing Chen Ph.D.Chief Financial OfficerDr. Peter Huang Ph.D.Chief Scientific OfficerMs. Christine ChiouSenior VP & Head of Investor RelationsMr. Frazor Titus Edmondson III (Age 58)J.D., Chief Legal Officer & Corporate Secretary Comp: $829kMs. Ann E. Beasley J.D.Chief Compliance OfficerDr. Ning Xu M.D. (Age 59)Executive VP & Head of Clinical Operations More ExecutivesKey CompetitorsViking TherapeuticsNASDAQ:VKTXInsmedNASDAQ:INSMIntra-Cellular TherapiesNASDAQ:ITCIJazz PharmaceuticalsNASDAQ:JAZZBlueprint MedicinesNASDAQ:BPMCView All CompetitorsInsiders & InstitutionsSwedbank ABBought 15,200 shares on 5/21/2024Ownership: 0.015%Tidal Investments LLCBought 20,858 shares on 5/17/2024Ownership: 0.021%Janus Henderson Group PLCBought 387,729 shares on 5/16/2024Ownership: 4.463%Price T Rowe Associates Inc. MDSold 1,053,668 shares on 5/15/2024Ownership: 1.664%Bamco Inc. NYBought 108,991 shares on 5/15/2024Ownership: 1.613%View All Insider TransactionsView All Institutional Transactions ZLAB Stock Analysis - Frequently Asked Questions Should I buy or sell Zai Lab stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZLAB shares. View ZLAB analyst ratings or view top-rated stocks. What is Zai Lab's stock price target for 2024? 5 Wall Street research analysts have issued twelve-month price targets for Zai Lab's shares. Their ZLAB share price targets range from $47.50 to $73.34. On average, they expect the company's share price to reach $64.22 in the next year. This suggests a possible upside of 257.6% from the stock's current price. View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts. How have ZLAB shares performed in 2024? Zai Lab's stock was trading at $27.33 on January 1st, 2024. Since then, ZLAB shares have decreased by 34.3% and is now trading at $17.96. View the best growth stocks for 2024 here. Are investors shorting Zai Lab? Zai Lab saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 3,280,000 shares, a drop of 24.8% from the April 30th total of 4,360,000 shares. Based on an average daily trading volume, of 641,300 shares, the days-to-cover ratio is presently 5.1 days. View Zai Lab's Short Interest. When is Zai Lab's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our ZLAB earnings forecast. How were Zai Lab's earnings last quarter? Zai Lab Limited (NASDAQ:ZLAB) posted its earnings results on Wednesday, May, 8th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.38. The business had revenue of $87.15 million for the quarter, compared to analyst estimates of $77.07 million. Zai Lab had a negative net margin of 116.45% and a negative trailing twelve-month return on equity of 40.21%. During the same period last year, the company earned ($0.51) EPS. What ETFs hold Zai Lab's stock? ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB), Amplify Treatments, Testing and Advancements ETF (GERM), Virtus LifeSci Biotech Products ETF (BBP) and ALPS Medical Breakthroughs ETF (SBIO).Invesco Golden Dragon China ETF (PGJ). What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN). When did Zai Lab IPO? Zai Lab (ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO. Who are Zai Lab's major shareholders? Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Capital World Investors (5.73%), Janus Henderson Group PLC (4.46%), Price T Rowe Associates Inc. MD (1.66%), Bamco Inc. NY (1.61%), Clearbridge Investments LLC (0.82%) and Vivo Capital LLC (0.54%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Joshua L Smiley, Peter Wirth, Rafael Amado, Tao Fu, William Ki Chul Cho, William Lis, Yajing Chen and Ying Du. View institutional ownership trends. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZLAB) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe 7th Trillion Dollar Company?The Oxford ClubThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.